Marinus's anti-epileptic positive in Phase II
This article was originally published in Scrip
Executive Summary
Marinus Pharmaceuticals' anti-epileptic ganaxolone has met the primary endpoint of its Phase II trial as an adjunctive treatment for adult patients with partial onset seizures.